Haemate (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Haemate is indicated for the management of bleeding episodes and perioperative prophylaxis in patients with specific inherited clotting deficiencies.

• Replacement therapy for hemophilia A patients with factor VIII deficiency.
• Treatment of von Willebrand disease types 1, 2, and 3 to restore von Willebrand factor activity.
• Control of acute bleeding episodes such as joint or muscle hemorrhages.
• Surgical or dental procedure prophylaxis to maintain hemostasis.
• Long‑term secondary prophylaxis in individuals with severe hemophilia A.
• Adjunctive therapy in combination with other clotting factor concentrates when individualized dosing is required.

The safety profile of Haemate reflects the typical reactions observed with plasma‑derived clotting factor concentrates.

Common

• Mild infusion site erythema or swelling.
• Transient headache or fatigue.
• Low‑grade fever within 24 hours of administration.
• Transient nausea or vomiting.
• Mild joint stiffness lasting less than 48 hours.
• Mild increase in liver enzymes (ALT/AST) that resolves spontaneously.

Serious

• Development of inhibitors (antibodies) against factor VIII or von Willebrand factor.
• Allergic reactions ranging from urticaria to anaphylaxis.
• Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism.
• Hemolytic reactions due to contaminant proteins.
• Renal impairment exacerbated by volume overload.
• Severe hypersensitivity leading to bronchospasm or hypotension.

When prescribing Haemate, clinicians should consider several precautionary measures to ensure safe and effective use.

• Verify the patient’s baseline factor VIII and von Willebrand factor levels before initiating therapy.
• Screen for a history of inhibitor development or previous allergic reactions to plasma‑derived products.
• Monitor for signs of thrombosis, especially in patients with cardiovascular risk factors.
• Assess renal and hepatic function periodically during long‑term treatment.
• Use the lowest effective dose to maintain hemostasis and reduce exposure.
• Counsel patients on proper storage, handling, and disposal of the injectable solution.
• Document any adverse events promptly in the patient’s medical record.

Haemate may interact with other medicines that affect coagulation or the immune system; awareness of these interactions helps optimize therapy.

Avoid

• Concomitant use of other plasma‑derived clotting factor concentrates without specialist guidance.
• Administration of high‑dose pro‑coagulant agents (e.g., recombinant activated factor VII) that could increase thrombotic risk.
• Concurrent use of desmopressin (DDAVP) without monitoring, as it may cause additive hemostatic effect.

Use with caution

• Antifibrinolytic agents such as tranexamic acid, which may enhance clot stability but require monitoring.
• Immunosuppressive drugs that could alter inhibitor development, including rituximab or cyclophosphamide.
• Certain antibiotics (e.g., vancomycin) that have been associated with rare hypersensitivity reactions when combined with plasma products.